Ketamine Troches vs. IV Infusions: A Complete Comparison

Ketamine Troches vs. IV Infusions: How the Two Options Compare

Ketamine troches and IV ketamine infusions are the two most common ways patients access ketamine therapy for depression, anxiety, PTSD, and chronic pain, and choosing between ketamine troches vs IV infusion usually comes down to how much bioavailability, speed, cost, and clinical supervision matter for your treatment plan. Both routes deliver the same active medication, racemic ketamine, a dissociative anesthetic that has shown antidepressant effects at sub-anesthetic doses. IV infusions are administered in a clinic under direct medical supervision, sending ketamine straight into the bloodstream for close to complete bioavailability. Ketamine troches are compounded lozenges that dissolve under the tongue at home, absorbed through the oral mucosa with roughly 25-30% bioavailability. This guide compares the two routes across bioavailability, onset, cost, convenience, supervision, and effectiveness so you can talk through the tradeoffs with your provider.

Bioavailability and Onset

Bioavailability, the percentage of a dose that reaches the bloodstream and becomes available to affect the body, is the biggest pharmacological difference between the two routes. IV infusions bypass digestion and the mouth entirely, so nearly the full dose reaches circulation. Troches rely on absorption through the tissue under the tongue, and any medication that gets swallowed with saliva passes through first-pass liver metabolism, which reduces how much ultimately reaches the bloodstream.

The tradeoff is that troches produce a more gradual rise in blood levels, which many patients experience as a smoother, less jarring onset compared to the sharper peak of an IV infusion. For a closer look at how absorption unfolds minute by minute, see our troche onset and duration timeline.

Cost Comparison

Cost is where troches have a clear advantage. A single troche dose typically runs $1-15, and monthly troche therapy, including provider consultations, usually totals $100-400. IV infusions cost $400-800 per session in a clinic, and an initial induction series of six infusions can run $2,400-4,800 before any maintenance sessions, which are typically needed every 3-6 weeks. Over a 12-month period, troche therapy may cost $1,200-4,800 compared to $4,800-12,000 or more for IV infusions. Neither troches nor standard IV ketamine infusions are typically covered by insurance, though FDA-approved esketamine (Spravato) nasal spray, a related but separate treatment approved for treatment-resistant depression, may be covered in some cases when administered at a certified clinic, according to the FDA's approval announcement. See our breakdown of what ketamine troches cost and our guide to the ketamine insurance coverage gap for ways to manage out-of-pocket expenses.

Convenience and Accessibility

Troches let patients dose at home on their own schedule, without missing work or arranging a ride to a clinic. IV infusions require traveling to a specialized clinic, scheduling around business hours, and setting aside 2-3 hours per visit once monitoring time is included. Neither treatment allows you to drive afterward, so transportation still needs to be arranged either way. For patients in rural areas or those with mobility limitations, the ability to take a troche at home rather than commute to an infusion center can be the deciding factor in whether treatment happens consistently.

Clinical Supervision

IV infusions include direct medical monitoring for the full session, with vital sign tracking and staff on hand to intervene if a patient has an adverse reaction. That level of supervision matters most for patients who are new to ketamine, have cardiovascular risk factors, are on higher-dose protocols, or have had a difficult reaction in the past. Troche therapy typically relies on periodic telehealth check-ins with a prescribing provider between doses, with the patient monitoring their own response at home. That model works well once a patient has an established response to ketamine, but it means less real-time support during the dose itself. Our troche safety guide and telehealth provider directory cover what that oversight looks like in practice.

Effectiveness

Research comparing sublingual or oral ketamine to IV ketamine for depression is still developing. IV ketamine has the most established evidence base, particularly for rapid response in treatment-resistant depression, a diagnosis given when a patient has not responded to at least two adequate trials of standard antidepressants. Sublingual ketamine has shown promising results in several studies, though typically with a less rapid onset of antidepressant effect than IV. According to the National Institute of Mental Health, ketamine and esketamine remain active areas of depression research, and much of the controlled trial evidence to date has focused on IV and intranasal routes rather than sublingual troches. For maintenance therapy after an initial response, troches may be equally effective and more sustainable long-term, since patients can continue treatment without repeated clinic visits. Both routes show efficacy for chronic pain conditions as well. See our comparison of remission rates between troches and infusions for outcome-specific data, and our guide to intranasal esketamine if you're weighing a third, FDA-approved option.